Management of recurrent hepatitis C after liver transplantation: a concise review
- PMID: 11007212
- DOI: 10.1111/j.1572-0241.2000.02296.x
Management of recurrent hepatitis C after liver transplantation: a concise review
Abstract
Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation.
Similar articles
-
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.Liver Transpl. 2004 Feb;10(2):199-207. doi: 10.1002/lt.20074. Liver Transpl. 2004. PMID: 14762857 Clinical Trial.
-
Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.Liver Transpl. 2001 Oct;7(10):863-9. doi: 10.1053/jlts.2001.27869. Liver Transpl. 2001. PMID: 11679984 Clinical Trial.
-
Chronic hepatitis C virus infection in renal transplant: treatment and outcome.Clin Transplant. 2006 Nov-Dec;20(6):677-83. doi: 10.1111/j.1399-0012.2006.00534.x. Clin Transplant. 2006. PMID: 17100715
-
Review article: the treatment of hepatitis C virus recurrence after liver transplantation.Aliment Pharmacol Ther. 2007 Jul 15;26(2):127-40. doi: 10.1111/j.1365-2036.2007.03364.x. Aliment Pharmacol Ther. 2007. PMID: 17593060 Review.
-
Hepatitis C virus in the transplant setting.Antivir Ther. 1998;3(Suppl 3):125-36. Antivir Ther. 1998. PMID: 10726062 Review.
Cited by
-
Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals.Mucosal Immunol. 2017 Jan;10(1):58-68. doi: 10.1038/mi.2016.39. Epub 2016 May 4. Mucosal Immunol. 2017. PMID: 27143301
-
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.Hepatology. 2012 Jul;56(1):300-10. doi: 10.1002/hep.25613. Epub 2012 Jun 18. Hepatology. 2012. PMID: 22278637 Free PMC article.
-
Viral prophylaxis in organ transplant patients.Drugs. 2004;64(24):2763-92. doi: 10.2165/00003495-200464240-00004. Drugs. 2004. PMID: 15563248 Review.
-
Effects of hepatitis C virus infection and its recurrence after liver transplantation on functional performance and health-related quality of life.J Gastrointest Surg. 2002 Jan-Feb;6(1):108-15. doi: 10.1016/s1091-255x(01)00002-6. J Gastrointest Surg. 2002. PMID: 11986026
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
